The 340B Battleground: Alliance Theory and the War Over Pharmaceutical Revenue in Los Angeles

Players in Los Angeles’s HIV and STD response do not compete for authority by openly saying they want control over the billions in pharmaceutical revenue that flow through the 340B Drug Pricing Program. They compete by invoking moral languages that frame their authority as protecting vulnerable communities from corporate greed, defending the continuum of care, and preventing healthcare redlining. This is the core insight of David Pinsof’s Alliance Theory. Moral vocabularies are coalition technologies. They recruit allies, define legitimacy, and justify control over institutions. In Los Angeles, the dominant vocabulary in this specific fight is equity, anti-displacement, stigma-free care, and the survival of community-based providers. These terms do not merely describe goals. They create a framework in which authority over pharmaceutical revenue becomes inseparable from moral virtue. The system does not merely dispense medication. It sustains the infrastructure that keeps marginalized people alive. Whoever controls that definition controls the most powerful legitimating language available in a fight that is, at its core, about money.
Los Angeles presents itself as a unified biomedical and social response to HIV, mpox, and rising STIs. In practice it is a structured arena of elite competition organized around the Division of HIV and STD Programs, the Commission on HIV, major nonprofit contractors, pharmaceutical manufacturers, Pharmacy Benefit Managers, and state regulators. Rival coalitions do not reject the mission of ending the epidemic. They compete to define what protecting that mission requires, who has the authority to make that determination, and which financial structures should follow. The 340B program sits at the center of this struggle not because anyone planned it that way but because it turned out to generate the kind of revenue that produces genuine political independence, and genuine political independence changes what an organization can do and what it must protect.
Three domains concentrate this struggle more than any others. Epistemic authority over what the 340B program is for and whether current uses serve its original purpose, the administrative and governance structure that determines who can audit and direct pharmaceutical revenues, and the legislative and legal battlefronts where those questions get resolved for every provider in California. Whoever governs these domains governs the financial base of the entire HIV services infrastructure in Los Angeles. What looks like a debate over PBM reimbursement rates, Medi-Cal carve-outs, or performance-based contracting is, underneath, a contest over who gets to define the purpose of pharmaceutical profit and therefore who controls the revenue it generates.
The epistemic domain comes first because it governs the terms on which every other competition is conducted. The 340B program was created in 1992 to allow safety-net providers to stretch limited federal resources by purchasing drugs at steep discounts and using the margin to fund services for uninsured and underserved patients. That original purpose is now a contested text, and every coalition reads it differently.
The equity-and-access coalition, led by AIDS Healthcare Foundation, APLA Health, and the Los Angeles LGBT Center, argues that 340B revenue is not profit. It is the financial substrate of the entire care model. The spread between discounted acquisition costs and insurance reimbursement funds food banks, housing navigation, legal aid, outreach workers, and the full range of wraparound services that keep HIV-positive patients engaged in care. To strip that revenue through discriminatory reimbursement or state carve-outs is not reform. It is healthcare redlining. The PBM that pays a 340B pharmacy less than a commercial pharmacy for the same drug is not lowering consumer costs. It is steering patients toward corporate mail-order systems and away from community-based providers who know their names.
Stephen P. Turner’s essentialist diagnosis applies here as it does across every case in this series. The equity coalition claims that the original purpose of 340B is being faithfully transmitted by providers who use the revenue to fund comprehensive care for marginalized patients, and that PBMs and state administrators who challenge this use are corrupting a program they do not understand. Turner’s response is that even statutory purposes are transmitted through human institutions that introduce their own selections and distortions. The 1992 legislation did not specify that 340B revenues should fund ballot initiatives, political campaigns, or multi-billion-dollar global expansion. Those uses emerged from the organizational logic of entities that found themselves with discretionary revenue and the capacity to act on it. The coalition presents its current use of the program as faithful stewardship. Whether that framing survives scrutiny depends entirely on whose definition of fidelity gets institutionalized.
The reform coalition, assembled from PBMs, their legislative allies, some fiscal watchdogs, and critics of large nonprofit consolidation, uses the language of lowering consumer costs, ending nonprofit profiteering, and returning 340B savings to patients. Its claim is that the billions generated through 340B have accumulated in the executive structures of large organizations rather than flowing to the marginalized patients the program was designed to serve. AHF, it notes, reports over two billion dollars in annual global revenue, operates pharmacies as profit centers, and spends heavily on political campaigns far outside its original clinical mission. The equity coalition frames this critique as corporate attack on community care. The reform coalition frames it as accountability for a program that has outgrown its statutory purpose.
Each side claims to honor the original intent of 340B. Each selects from the same legislative history to support incompatible conclusions about what that intent requires today.
The governance domain is where those competing definitions become institutional control. The Division of HIV and STD Programs manages contracts, surveillance, and strategic direction across a network of providers whose financial independence varies dramatically. DHSP has the formal authority to set performance requirements. AHF has the financial independence to resist them.
That asymmetry defines the governance struggle. DHSP uses the language of coordination, accountability, and equity metrics to argue that 340B-rich nonprofits must demonstrate their revenue serves public health goals. Its claim is that providers who generate hundreds of millions in pharmaceutical margins and then use those margins to fund political campaigns and housing ballot measures have drifted from their mission in ways that warrant oversight. The independent-provider coalition uses the language of private revenue, organizational autonomy, and the limits of government authority to argue that 340B income is not a public grant and cannot be audited or redirected by county administrators. AHF’s position is the clearest statement of this claim: the money is ours, the patients are ours, and the county’s performance-based contracting is administrative overreach dressed in the language of equity.
Pinsof’s framework decodes this move precisely. By framing pharmaceutical revenue as private and therefore beyond public accountability, the independent-provider coalition converts organizational financial independence into a principled limit on government authority. The regulator who demands accounting for 340B margins is not ensuring stewardship. He is attacking the infrastructure that saves lives. The coalition technology here is especially powerful because it fuses financial self-interest with humanitarian necessity in a single rhetorical gesture.
The California Medi-Cal Rx transition sharpened this conflict by actually moving the financial landscape. The state’s centralization of the pharmacy benefit under Medi-Cal Rx reduced the ability of Los Angeles nonprofits to capture the spread on antiretrovirals, creating a revenue gap that had been quietly funding services the public never knew the 340B model was supporting. The response from Sacramento was a series of equity grants designed to backfill the lost revenue. That substitution is structurally significant. It shifted power from independent providers back toward the state and county, because providers must now compete for grants by demonstrating compliance with state-defined equity metrics. The discretionary revenue that gave AHF its political independence was partly replaced by conditional public money that requires justification. The cage is not fully closed. But it has moved.
The legislative battleground is where the governance struggle takes its most explicit form. SB 900, currently debated in Sacramento, seeks to prohibit PBMs from paying 340B pharmacies less than commercial pharmacies for the same drug. AHF and the Los Angeles LGBT Center have formed an alliance around this bill, framing discriminatory reimbursement as a civil rights issue for LGBTQ+ communities. That framing is the coalition technology in operation. A dispute over pharmacy reimbursement rates becomes a civil rights fight, recruiting allies far beyond the pharmaceutical policy world and making opposition politically costly for legislators who would otherwise find the technical argument easy to sidestep.
The PBM coalition counters with the language of consumer costs and market efficiency, arguing that the spread captured by 340B entities inflates premiums and insurance costs without delivering demonstrably better patient outcomes. CVS Caremark and similar entities position mail-order pharmacies as cost-effective alternatives and frame anti-steering arguments as nonprofit protectionism. Both coalitions deploy the patient as the central moral figure. One claims the patient needs a community pharmacist who knows his history. The other claims the patient deserves lower drug costs. Both select the evidence that supports their framing and present that selection as objective concern for the people the program is meant to serve.
The funding and service allocation domain is where the abstract fight over 340B purpose becomes a contest over organizational survival. Clinics that built their service models on pharmaceutical margins now face a structural question. If those margins contract, which services survive? The wraparound model, food assistance, housing navigation, legal aid, depends on revenue that was never publicly debated or democratically allocated. It emerged from the intersection of a federal drug discount program, a specific patient population on lifelong medication, and a nonprofit sector with the administrative capacity to capture and deploy the spread.
That origin matters for the current conflict. The equity-and-access coalition argues that the social services enabled by 340B revenue represent a genuine public good that justifies protecting the revenue stream by any means available, including litigation, legislation, and political spending. The accountability coalition argues that public health infrastructure should not depend on pharmaceutical arbitrage and that services funded through opaque margins should be funded through transparent appropriations subject to democratic oversight. Both are right about something. The wraparound services are real and valuable. The financing mechanism is genuinely opaque and structurally anomalous.
AHF’s trajectory illustrates the larger pattern. A crisis service provider became a pharmaceutical revenue engine, which became a financially independent political actor with cross-domain influence in health, housing, and local governance. That path required no single corrupt decision. It required an organization to follow the institutional logic of its revenue model to its conclusions. Pharmaceutical throughput rewards scale. Scale enables political spending. Political spending protects the conditions that enable throughput. Housing stability for low-income patients overlaps with the tenant protection politics AHF funds. Those overlaps are real. They are also convenient, which does not make them false but does make them worth examining.
The overall pattern holds across all three domains. Every coalition claims authority by asserting possession of something essential. AHF claims the care infrastructure and patient relationships that no bureaucracy can replicate. DHSP claims the coordination authority and accountability structures that autonomous providers cannot self-impose. PBMs claim the market efficiency that benefits patients through lower premiums. Community providers claim the cultural competence and trust that mail-order systems cannot purchase. State administrators claim the equity metrics and democratic legitimacy that private revenue streams cannot provide.
None of these actors presents its position as interest in sustaining a revenue model worth billions annually. All present it as necessity grounded in public health and moral obligation.
The deeper conflict is structural. The system cannot admit it depends on pharmaceutical arbitrage without weakening its claim to pure humanitarian purpose. Its authority depends on appearing above the market even while operating within it at extraordinary scale. Reform coalitions cannot accept that framing because their legitimacy depends on exposing the financial logic that the moral language obscures.
What the conflict produces is not resolution but escalation. When the 340B revenue model is intact, its institutional definitions become the default structure for community-based HIV care across California. When that model is contested, as it is now through PBM reimbursement cuts, Medi-Cal carve-outs, federal funding disruptions, and performance-based contracting, the system fragments into parallel legitimacy structures with different financial bases, different definitions of accountability, and different claims about what the 340B program was ever for. The original coalitions are defending a world in which they generate and deploy revenue on terms they set. The reform coalitions are attacking that world by insisting that public health infrastructure funded through public programs must answer to the public. Neither side can concede the core point without collapsing its own coalition, which is why the Sacramento hearings continue, why each reimbursement policy change becomes a civil rights emergency, and why an argument about pharmacy spreads feels like an argument about everything.